Research on primary aldosteronism and its effects on hypertension
Official title: Chongqing Primary Aldosteronism Study
Run by Chongqing Medical University · NCT03224312 · Data updated 2026-11-12
This study is trying to understand how primary aldosteronism affects high blood pressure over time by looking at a large group of patients and collecting samples to find better ways to manage the condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | October 1, 2016 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | September 6, 2023 |
| Trial ID | NCT03224312 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are hypertensive patients who have completed aldosterone-renin ratio screening and are willing to provide informed consent.
✕Probably not a fit
Patients with severe cardiac, hepatic, or renal dysfunction, or those with other types of secondary hypertension, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a large cohort of patients with primary aldosteronism (PA) and essential hypertension, focusing on long-term follow-up of cardiovascular and renal outcomes. It will collect extensive biological samples, including blood, urine, and adrenal tissue, to create a comprehensive database for genomics, metabonomics, and proteomics analysis. The goal is to explore the mechanisms behind PA, identify risk factors, and develop diagnostic methods and biomarkers for better management of the condition.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of primary aldosteronism, potentially reducing cardiovascular and renal complications in affected patients.
How similar studies have gone: While this study builds on existing research in hypertension, its specific focus on primary aldosteronism and comprehensive biological analysis may offer novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. hypertensive patients who completed ARR screening and necessary further tests; 2. Voluntary to sign the informed consent. Exclusion Criteria: 1. patients with severe cardiac, hepatic or renal dysfunction; 2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.
Where it's running
-
Qifu Li
Chongqing, Chongqing Municipality, China Recruiting
Study contacts
- Study coordinator: Qifu Li, phD
- Email: liqifu@yeah.net
- Phone: +86 023-89011552
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Kidney stiffness measured by ultrasound in hypertension and healthy volunteers
This study tests whether kidney stiffness measured by a non-invasive ultrasound method differs between people with high blood pressure and healthy individuals.
-
Inclisiran vs. Statin for Primary Aldosteronism
This trial tests whether inclisiran plus amlodipine works differently from a statin-based approach in people with primary aldosteronism and high blood pressure.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Metomidate PET-CT vs Usual Care for Primary Aldosteronism
This study tests whether [11C] metomidate PET-CT can help orient treatment for people with primary aldosteronism compared with the usual adrenal venous sampling approach.
-
Captopril Test with LC-MS/MS for Aldosterone and Renin in Primary Aldosteronism
This study tests whether measuring aldosterone with LC-MS/MS during a captopril test can better diagnose primary aldosteronism.
-
Finerenone vs. Spironolactone for Primary Aldosteronism
This trial tests whether finerenone works as well as spironolactone to lower blood pressure and improve related health measures in adults with primary aldosteronism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.